前哨淋巴结活检与淋巴结清扫在中高级别子宫内膜癌分期中的对比评估
该前瞻性多中心队列研究纳入156例中高级别子宫内膜癌患者,所有患者均接受前哨淋巴结活检(SLNB)后行淋巴结清扫作为参考标准。SLNB算法灵敏度为96%,假阴性率4%,阴性预测值99%,仅1例(0.6%)被误分类。研究表明SLNB在高危淋巴结转移患者中具有可接受的诊断准确性,可作为手术分期的可行选择。
要点
- SLNB算法灵敏度96%,假阴性率4%,阴性预测值99%。
- 每患者SLN检出率97.4%,双侧检出率77.6%。
- 26%的淋巴结阳性病例位于传统盆腔清扫边界外或需免疫组化诊断。
核心结论
- 在高危淋巴结转移的高级别子宫内膜癌患者中,SLNB具有可接受的诊断准确性,并较淋巴结清扫提高了淋巴结阳性病例的检出。
- 研究结果表明SLNB是子宫内膜癌手术分期的一种可行选择。
研究设计与样本
- 前瞻性、多中心队列研究(SENTOR研究),2015年7月1日至2019年6月30日入组,因预设准确性标准提前终止。
- 纳入临床I期2级子宫内膜样或高级别子宫内膜癌患者,计划在加拿大大多伦多地区3个指定癌症中心接受腹腔镜或机器人子宫切除术并完成分期。
- 共纳入156例患者(中位年龄65.5岁,范围40-86岁;中位BMI 27.5,范围17.6-49.3),其中126例为高级别子宫内膜癌。
- 所有患者均接受SLNB后行淋巴结清扫作为参考标准;2级子宫内膜样癌患者仅行盆腔淋巴结清扫(PLND),高级别子宫内膜癌患者行PLND和腹主动脉旁淋巴结清扫(PALND)。
- 101例(80%)高级别子宫内膜癌患者还接受了PALND。
主要发现
- SLN检出率:每患者97.4%(95% CI,93.6%-99.3%),每半骨盆87.5%(95% CI,83.3%-91.0%),双侧77.6%(95% CI,70.2%-83.8%)。
- 27例(17%)患者存在淋巴结转移,其中26例被SLNB算法正确识别,灵敏度96%(95% CI,81%-100%),假阴性率4%(95% CI,0%-19%),阴性预测值99%(95% CI,96%-100%)。
- 仅1例患者(0.6%)被SLNB算法误分类。
- 27例淋巴结阳性患者中,7例(26%)的阳性淋巴结位于传统PLND边界外或需免疫组化才能诊断。
临床怎么用
- 对于中高级别子宫内膜癌患者,可考虑采用SLNB替代系统性淋巴结清扫进行手术分期。
- SLNB算法具有高灵敏度和阴性预测值,但需注意约26%的阳性淋巴结位于传统清扫边界外或需免疫组化辅助诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Whether sentinel lymph node biopsy (SLNB) can replace lymphadenectomy for surgical staging in patients with high-grade endometrial cancer (EC) is unclear. OBJECTIVE: To examine the diagnostic accuracy of, performance characteristics of, and morbidity associated with SLNB using indocyanine green in patients with intermediate- and high-grade EC. DESIGN, SETTING, AND PARTICIPANTS: In this prospective, multicenter cohort study (Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging [SENTOR] study), accrual occurred from July 1, 2015, to June 30, 2019, with early stoppage because of prespecified accuracy criteria. The study included patients with clinical stage I grade 2 endometrioid or high-grade EC scheduled to undergo laparoscopic or robotic hysterectomy with an intent to complete staging at 3 designated cancer centers in Toronto, Ontario, Canada. EXPOSURES: All patients underwent SLNB followed by lymphadenectomy as the reference standard. Patients with grade 2 endometrioid EC underwent pelvic lymphadenectomy (PLND) alone, and patients with high-grade EC underwent PLND and para-aortic lymphadenectomy (PALND). MAIN OUTCOMES AND MEASURES: The primary outcome was sensitivity of the SLNB algorithm. Secondary outcomes were additional measures of diagnostic accuracy, sentinel lymph node detection rates, and adverse events. RESULTS: The study enrolled 156 patients (median age, 65.5 years; range, 40-86 years; median body mass index [calculated as weight in kilograms divided by height in meters squared], 27.5; range, 17.6-49.3), including 126 with high-grade EC. All patients underwent SLNB and PLND, and 101 patients (80%) with high-grade EC also underwent PALND. Sentinel lymph node detection rates were 97.4% per patient (95% CI, 93.6%-99.3%), 87.5% per hemipelvis (95% CI, 83.3%-91.0%), and 77.6% bilaterally (95% CI, 70.2%-83.8%). Of 27 patients (17%) with nodal metastases, 26 patients were correctly identified by the SLNB algorithm, yielding a sensitivity of 96% (95% CI, 81%-100%), a false-negative rate of 4% (95% CI, 0%-19%), and a negative predictive value of 99% (95% CI, 96%-100%). Only 1 patient (0.6%) was misclassified by the SLNB algorithm. Seven of 27 patients with node-positive cancer (26%) were identified outside traditional PLND boundaries or required immunohistochemistry for diagnosis. CONCLUSIONS AND RELEVANCE: In this prospective cohort study, SLNB had acceptable diagnostic accuracy for patients with high-grade EC at increased risk of nodal metastases and improved the detection of node-positive cases compared with lymphadenectomy. The findings suggest that SLNB is a viable option for the surgical staging of EC.
引用
- Cusimano MC, Vicus D, Pulman K, et al. Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging. JAMA Surg. 2021. PMID: 33175109. doi:10.1001/jamasurg.2020.5060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。